What type of study is this?

This is a Meta-Analysis study (also classified as: Pre-Registered Trial, Systematic Review).

What question did this study set out to answer?

Evaluate bleeding and hypertension incidence in patients with hematologic malignancies treated with next-generation BTK inhibitors.

December 8, 2025Blood

Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials

View Full Paper

Ask AI

Bookmark

Authors

DJDaniel JonesSunrise Medical (United States)RSRamaditya SrinivasmurthyMount Sinai Hospital AKAmna KhalidElmhurst Hospital Center

Discussion

Member takes

Implication

Meta-analysis highlights increased bleeding risk but similar hypertension rates in patients with hematologic malignancies treated with BTK inhibitors.

Key Points

Evaluate bleeding and hypertension incidence in patients with hematologic malignancies treated with next-generation BTK inhibitors.
Systematic review and meta-analysis of randomized controlled trials
Included trials using next-generation BTK inhibitors in hematologic malignancies
Pooled risk ratios and confidence intervals calculated
Higher incidence of any-grade bleeding in BTKi group (32.38%) versus control (20.10%)
No significant difference in high-grade bleeding or hypertension between BTKi and control groups
Subgroup analysis showed significantly higher any-grade bleeding in BTKi group (32.06%) compared to control (9.73%)

Cite This Study

Jones et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0c4 https://doi.org/10.1182/blood-2025-2739

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis highlights increased bleeding risk but similar hypertension rates in patients with hematologic malignancies treated with BTK inhibitors.

Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Incidence of bleeding and hypertension in patients with hematologic malignancies treated with next-generation Bruton tyrosine kinase (BTK) inhibitors: A meta-analysis of randomized controlled trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider